There is no clinical biomarker that predicts which patients with stage II or III colon cancers are at risk for developing metastases. A bioinformatics approach using the Mutant-Allele Tumor Heterogeneity score for tumor heterogeneity might identify this high-risk subset of patients to tailor adjuvant therapies and surveillance. Background: Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease. Patients and Methods: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancer patient samples. Results: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups. When heterogeneity was quantified using the Mutant-Allele Tumor Heterogeneity (MATH) score, there was a strong correlation between higher MATH score and risk of metastases. Conclusions: Measures of tumor heterogeneity might be useful biomarkers for identifying patients with colon cancer who are at risk of developing metastases. This might allow for more specific, tailored follow-up and adjuvant therapies after standard surgery.
Introduction
Colorectal cancer remains a leading cause of cancer-related mortality worldwide. Most deaths from this disease are not from the primary tumor itself, but from metastatic disease. Identifying the patients who are most likely to develop metastases remains an important clinical and research goal. The current paradigm for treatment is on the basis of gross pathologic evaluation. Early staged (I and II) low-risk tumors are treated with surgical resection alone. As standard of care, adjuvant therapies are not offered, but up to 20% of patients diagnosed as early stage will go on to develop metastatic disease. [1] [2] [3] Patients with lymph node metastasis, stage III, are treated with resection and are offered adjuvant cytotoxic chemotherapies as standard of care. Despite this aggressive, multimodality approach, approximately 50% of stage III patients will subsequently develop metastatic disease. 3 Unfortunately, there is no clinically available biomarker to reliably predict which stage II and III patients are at risk of developing advanced metastatic disease. Next-generation sequencing provides a powerful new approach to characterize tumors, and has ushered in a new era of 'personalized medicine,' by providing a means of matching patients whose tumors harbor specific driver mutations to drugs that specifically target those lesions. However, detailed analysis of tumor mutations, made possible by "deep" sequencing at high read-depth to detect rare mutations, has revealed extraordinary heterogeneity in tumors, especially as they evolve and progress to become metastatic. 4 This might be especially true in colorectal cancer, which is often associated with mutations in genes that affect DNA repair pathways.
Intratumoral heterogeneity has been linked to metastatic potential in animal models, 7 and is likely to be an important prognostic feature of human disease. Human tumors that are more heterogeneous are thought to include tumor subclones that have evolved to evade standard therapies or to increase their ability to metastasize to distant sites. 8 Recently, next-generation sequencing approaches that make use of "deep" sequencing to analyze tumor subclones have been described for evaluating the importance of tumor heterogeneity in diverse cancer types, including leukemias, head and neck tumors, and rectal cancer. 4, [9] [10] [11] We hypothesized that these approaches would also provide information about the tumor heterogeneity, and perhaps the potential for metastasis, in colon cancer. Our results suggest that measures of tumor heterogeneity could be useful biomarkers for identifying patients at highest risk of metastatic disease.
Patients and Methods
Seven patients with either stage II or III colon cancer were identified in a prospective database in the Division of Surgical Oncology. After institutional review board approval, corresponding normal and colon tumor formalin-fixed, paraffin-embedded blocks of these patient samples were obtained from the University of New Mexico (UNM) Cancer Center Human Tissue Repository. Upon successful extraction of DNA using standard techniques, samples were analyzed using the Ion Ampliseq Comprehensive Cancer panel assay, which targets more than 400 cancer-relevant genes. Sequencing was performed on the Ion Proton instrument as described by the manufacturer (Thermo Fisher Scientific, Waltham, MA), generating average read depths of > 1000 times across the targeted regions. As quality control, only samples that yielded > 500 times the average coverage for all 4 12 with Bioconductor (version 3.2). 13 Analyses were limited to single nucleotide variants (no indels) with read depth > 50 and at least 5 reads in each direction. Note: only tumor samples were analyzed with this 409-gene panel. Although some of the variants detected arise from the germline, no germline (normal) samples were analyzed for these studies. The R scripts and the VCF files used for these analyses are available for download 14 (Note: although these data were collected before the implementation of the current National Institutes of Health [NIH] policy on genome data-sharing, the deidentified VCF files are considered level 3 and are not subject to controlled access). Variant allele frequencies (VAF) were calculated as the ratio of alternate allele observations to the read depth at each position. Because we did not analyze normal germline samples, we modified the Mutant-Allele Tumor Heterogeneity (MATH) score 10 to include all heterozygous (genotype "0/1") variants with VAF between 0.05 and 0.75, calculated as 100 times the median absolute deviation (MAD)/median of the VAF. The comparisons of MATH score between stages were conducted using t test statistics after checking the required assumptions of the distribution and equal variance. For principal components analysis, the data set was first limited to a subset of single nucleotide polymorphisms that differed the most between stage II and III patients, then plots were prepared using plotMDS, part of the Bioconductor package LIMMA. 15 To test the reproducibility of the aforementioned test, we identified 3 additional colon tumor samples that had originally been diagnosed as stage II tumors, but subsequently went on to develop metastatic disease. As described previously, the same procedure was used to quantify the tumor heterogeneity by determining the corresponding the MATH score.
Results
We performed high read-depth ("deep") sequencing of > 400 cancer-relevant genes on a group of 7 colon cancer samples divided between stages II and III, which were obtained from the UNM Cancer Center Human Tissue Repository. The DNA samples were obtained from diagnostic formalin fixed paraffin embedded samples, analyzed using the Ion Ampliseq Comprehensive Cancer Panel assay, and sequencing was performed on the Ion Proton nextgeneration sequencing instrument (Thermo Fisher Scientific), generating average read depths of > 1000 times across the targeted regions. Matched normal samples were analyzed using Ion Ampliseq Exome sequencing assays, which generated average read depths of > 100 times across the targeted regions. For these studies, only tumor samples were analyzed, similar to practices commonly performed by clinical laboratories when performing diagnostic tests. 
MATH Scores Correlate With Colon Cancer Metastasis
As summarized in Figure 1 , heterozygous tumor-specific mutations were detected in numerous genes, and the same genes were often found mutated in several tumor samples. These results fit with models of colon cancer carcinogenesis that predict the involvement of a limited number of driver mutations involved in the development of the primary tumor. 16, 17 Thus, the mutational spectrum observed in colon carcinoma, even in this small cohort of samples, was quite diverse. However, a more complicated picture emerged when we investigated the VAF detected in various samples. In the DNA of normal cells, allele frequencies are expected to cluster around 50% for heterozygous variants, and around 0% or 100% for homozygous alleles. Figure 2 shows the distributions of VAF for heterozygous tumor variants for the 26 most commonly mutated genes in the tumors analyzed. The results show that VAF varied considerably, from as low as 10% to as high as 80%. For example, we detected mutations in the KMT2C (MLL3) gene at VAF between 0.15 and 0.45 in several samples. Because these mutations are heterozygous, the results suggest that the percentage of cells harboring the observed mutations varies from approximately 30% to approximately 90% of the cells in the tumors. Similar results were obtained for all of the detected tumor-specific mutations. Because all of the tumors were judged to be at least 40% tumor cells in microscopic analysis, these results suggest that subclones with different sets of mutations exist in many of the tumors.
Although some of the tumor heterogeneity is due to the presence of normal and tumor cells in the samples, there is also evidence that the tumors are themselves heterogeneous, suggesting the presence of multiple tumor subclones. As a first step in analyzing the tumor heterogeneity in these samples, we performed principal components analysis on the VAF observed in the tumors. As shown in Figure 3A , the stage II tumors (black) clustered tightly together, whereas the stage III tumors (red) were more heterogeneous and more scattered.
Tumor heterogeneity has been extensively analyzed in acute myeloid leukemias, and several types of plots have been described for displaying the data.
9 Figure 3B and C show plots of variant allele frequency versus read depth 9 for 2 tumor samples, which had similar numbers of tumor-specific heterozygous mutations. In Figure 3B (tumor 4117), there is a distinct cluster of variants at approximately 50% variant allele frequency and smaller clusters at 0% and 100%. Although there are some mutations at intermediate VAF (shaded red), most of the variants cluster near 50%. However, we noted that some samples had a more complex composition. Figure 3C (tumor 3256) shows a much more spread-out, diverse spectrum of VAF. This "spread" might be evidence of significant tumor heterogeneity, likely caused by the presence of several subclones within the tumor. This type of heterogeneity in tumors is thought to lead to the outgrowth of therapy-resistant clones, or tumor evolution, and eventually to metastatic disease. 18, 19 Recently, the MATH score was developed to quantify differences in the dispersion or spread of allele frequencies in head and neck tumor samples. 10 The MATH score is calculated as 100 times the MAD/median of the VAF, and describes the ratio of the width of the data to the center of the distribution-effectively a score describing the spread in the data. In most cases, the MATH score is applied to exome sequencing data from germline (normal) and tumor, so that the tumor-specific mutations can be identified. However, we modified this approach, using the data from a targeted CYP2D6  DST  FANCD2  FANCA  FGFR3  FGFR4  FN1  GATA2  HNF1A  IGF1R  KDR  KMT2C  LRP1B  MUC1  NUP98  PML  PTCH1  RNF213  ROS1  SEPT9  TAF1L  TAL1  THBS1  TNFRSF14 Figure 3B shows strong clustering of the variants at 50% VAF and has a low MATH score of 9.08. In contrast, sample 3256 in Figure 3C shows a widely spread distribution of allele frequencies and has a high MATH score of 25.24. Thus, the MATH score provides a quantitative measure of the degree of heterogeneity in a tumor sample. We calculated and compared the MATH scores for our cohort of colon cancer samples and found that the MATH score was strongly associated with tumor stage. As shown in Figure 4A , stage II tumors had low MATH scores and the MATH scores were significantly (P ¼ .016) higher in stage III tumors. The finding that more advanced tumors have greater tumor heterogeneity is consistent with the hypothesis that the presence of more tumor subclones (more heterogeneity) is likely to lead to selection for resistant and more aggressive clones that grow, metastasize, and lead to recurrent disease after chemotherapy.
Variant Allele Frequency
To validate our results, we selected 3 additional colon tumor samples that were initially diagnosed as stage II, but subsequently developed metastases. We compared them with the original stage II samples described previously. As shown in Figure 4B , the 3 samples that were initially labeled as stage II but later formed metastatic disease had higher MATH scores (P ¼ .025) than the stage II tumors that did not form metastases. These results suggest that measures of tumor heterogeneity, such as the MATH score, might be useful for identifying patients who should receive additional therapy or be monitored more aggressively for the development of metastatic disease.
Discussion
Colorectal cancer remains a leading cause of cancer-related morbidity and mortality worldwide. Being able to predict which patients with stage II or III disease will eventually present with recurrent or metastatic disease remains a clinical challenge. Our application of the MATH score to a set of human colon cancer samples showed that higher MATH scores are indicative of increased tumor heterogeneity and are correlated with a higher stage of disease. Stage III patients had a higher MATH score than the Traditional bioinformatics approaches have attempted to try to identify high-risk stage II and III patients using a number of tumor gene expression profiling assays to predict overall patient outcome and responsiveness to chemotherapy. [20] [21] [22] [23] [24] [25] [26] [27] Although responsiveness to adjuvant therapy has not been realized by these assays, some have been able to show a correlation between survival and a certain gene profile. However, there is little to no overlap in the demonstrated genes of significance between the assays and more importantly, the validation sets are small or not representative of the patient subgroups. Thus, there still remains a critical need to identify a reliable biomarker for high-risk stage II and stage III patients with colon cancer. Furthermore, if tumors are composed of several subclones, sampling different parts of a tumor could result in different lists of tumor mutations. The existence of intratumor heterogeneity has been noted for some time in the literature. With technical advancements in highresolution genomewide studies, this heterogeneity has been shown. In fact, synonymous drivers of mutations might arise independently in distinct clones and these clones might show unique diagnostic signatures from a single tumor, depending on the site of the biopsy. 28 In a review of intratumoral heterogeneity, Marusyk and colleagues delineate genetic and nongenetic causes of phenotypic heterogeneity of cancer cells. This heterogeneity has been shown to have significant importance in prognosis, risk of developing metastatic disease, and in the development of resistance to therapies. 29 Mroz and colleagues developed the MATH score as a quantitative measure of intratumoral genetic heterogeneity and applied it to tumors of the head and neck. 10, 11 They confirmed that higher MATH scores were found in high-risk, poor outcome groups of patients with head and neck squamous cell cancers. Because colon tumors are often associated with microsatellite instability, it is possible that the increased MATH scores that we detected in samples destined for metastases could be related to increased genome instability. Future studies will address such questions.
Conclusion
Limitations of this study include the small sample size and the exploratory nature of a discovery study. To overcome this, we conducted a small independent data set for sensitivity analysis. Despite these limitations, the data might contribute to a key clinical challenge, which is to overcome the inability to predict which patients with stage II and stage III colon cancer will progress to metastatic disease.
Clinical Practice Points
These data show that a novel bioinformatics approach using the MATH score as a reflection of tumor heterogeneity might allow for identifying patients who are at risk for developing metastatic disease. Access to this type of information will allow for more directed follow-up and perhaps more personally tailored adjuvant therapies to alleviate the morbidity and mortality from colorectal cancers. preparation. Some experiments used the facilities or services provided by the Analytical and Translational Genomics Shared Resource, which is supported by the State of New Mexico and the UNM Comprehensive Cancer Center (P30CA118100).
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